CCTV's continuous exposure of potential rules leads to inflated drug prices, which makes people in the industry smell a bit different. "The guiding ideology of high-level determination to promote the adjustment of interest pattern to reduce the burden of financial expenditure is very clear. At present, the medical reform has not yet touched the fundamental interest chain. CCTV's report puts these problems that have existed for many years on the table, and the significance of the wind vane behind them deserves attention. " On November 22, Ge Jianqiu, vice president of Shanghai Pharmaceutical (601607), told reporters. Another person from the pharmaceutical industry told reporters that in his view, the change of the current situation of high drug prices lies in the change of the current system. And rectifying the middle link and clearing the circulation order will bear the brunt, which will also bring great changes to the field of medicine circulation. The middle link is interested in profit According to the person in charge of the sales agency, they sold clindamycin phosphate to the medical representative at a price of 4 yuan each, and the medical representative sold it to the hospital at a bid price of 11 yuan, with an intermediate price difference of 7 yuan. The middle price difference is "refund". "We have to admit that 20 buckles (that is, if the drug price is 10 yuan, it will be sold to the general contractor at 20% price, that is, 2 yuan, and the general contractor will be sold to the first level distributor at 10 yuan) or even lower ex factory price is prevalent in the industry, even if the potential rule interest in the sales cost of independently promoted new drug varieties is also large." Ge Jianqiu said that the content revealed by the report is a well-known hidden rule in the industry, which has lasted for many years. He told reporters that most pharmaceutical companies can't reach the hospital with their own sales ability and have to entrust intermediate agency companies to sell drugs. An important part of the work of these agency companies is to get through the intermediate links, including the pricing department, the bidding department, the hospital and medical students, and finally let the agent drugs be prescribed. "It is the industry's default to leave these gray things to the gray group." The existence of these large number of intermediate links is an important reason to gradually push up the price of drugs. "CCTV's report only reflects one aspect of the bidding price. There are also many drugs with low bidding price. Because these drugs are not reserved for the profits in the middle link, they are often unable to do so." The head of a pharmaceutical factory told reporters that if the bid price of drugs is too low, it is lower than the cost of regular manufacturers, either the lower limit of feeding, or the shutdown. This is one of the reasons why some good and cheap drugs are not found in the market. The previous shortage of protamine is a typical case. "All pharmaceutical companies, including pharmaceutical companies, know that if a drug is to win the bid, it must win at a high price. If it is not to win at a high price, it is a dead bid." Ge Jianqiu believes that the current bidding system is an important reason for the high drug price. "Government bidding only allows more power to enter the rent-seeking market. It is suggested that government bidding should not be carried out. Bidding will only increase the cost of enterprises, and ultimately these intermediate costs will be borne by consumers." Zhu hengpeng, an expert in policy research of new medical reform and researcher of Chinese Academy of Social Sciences, also pointed out that the original intention of implementing drug bidding policy is to curb the false high price of drugs, but as a result, some interest groups have made use of the policy to follow the potential rules and collude with each other in the formulation of bid price, drug wholesale and sale and other links, forming a hidden interest chain Behind the rise in drug prices. Circulation link clearing According to the pharmaceutical industry research report released by Guolian securities recently, the root of the false high drug price is the long circulation link, but the relevant regulatory procurement department is also the profit maker. However, the old system of supporting doctors with drugs directly forces hospitals and doctors to profit from drugs. The recent increase of CCTV's attention to the new health care reform may mean that the policy may change. People familiar with the matter told reporters that the medical reform office of the State Council had held a meeting with the Ministry of Commerce. The Ministry of commerce is the Department in charge of medicine circulation. "This may be the prelude to the clean-up and circulation of the state." Industry insiders told reporters that at present, more than 10000 domestic pharmaceutical commercial enterprises may be cleaned up. The two vote system previously promoted in Guangdong and Fujian may be extended to a wider range. In the current drug sales, the enterprise delivers the goods to the agent, the agent delivers the goods to the commercial company, the commercial company is responsible for sending the goods to the hospital, the hospital pays to the commercial company, the commercial company settles with the agent, and then the agent pays to the enterprise. If two tickets system is implemented, a drug factory's outbound bill and a hospital's inbound bill, in addition, any other bills in the circulation link will not be recognized. In this way, there is no significance for middlemen. This also means that in the past, the phenomenon of multiple middlemen raising prices after the drugs leave the factory will be completely changed. With this, a large number of business companies attached to the gray model have been eliminated. In contrast, Sun Zhigang, director of the medical reform office of the State Council, also said in an interview with CCTV that the circulation link should be greatly reduced, the circulation cost should be greatly reduced, and the potential rules of this circulation link should be effectively contained. Ge Jianqiu calculated an account for the reporter: if the total amount of drugs purchased by the hospital in a year is 1 trillion yuan, then 60% of it, namely 600 billion yuan, may be divided up by various interest groups, with the consequence that the national finance has to spend 1 trillion yuan or more . If the chain of interests is broken, the enterprise will save 10% or 100 billion yuan for R & D investment to greatly enhance the core competitiveness, and the country can save 500 billion yuan for improving medical conditions and doctor treatment. "But it takes a lot of determination at the top." He said that if the country is determined to adjust, even if it does not increase the overall investment in health care, the actual use efficiency may increase several times. With the gradual privatization of some high-end medical services, the appropriate increase in the proportion of financial investment, the attraction of social capital and the rational use of tax leverage, medical reform will never become a burden. Zhejiang bamboo Pharmaceutical Co., Ltd. is located in Shangyu national economic and Technological Development Zone, Hangzhou Bay. It is a company that produces APIs, preparations, pharmaceutical intermediates and food additives. The total investment of the company's project is 1.05 billion yuan. The first phase of the project will be put into operation in June 2021. It is planned that the annual sales of the first phase of the project will be about 1 billion yuan after all the projects are put into normal operation. The company is positioned as a modern high-end pharmaceutical enterprise integrated with APIs. The finished drugs are mainly sold to the domestic market, aiming to become the largest supplier of national "4 + 7" volume procurement; in addition to ensuring the company's preparation production needs, most of the APIs are exported to the high-end markets in Europe and America, and the products reach the operation and production of the whole industrial chain. At present, our plant construction firmly follows the principle of "pay attention to progress, ensure safety, high quality and control cost", carries forward the enterprise spirit of "bamboo rooted, solid foundation", and advances our project construction efficiently, rapidly and orderly according to the progress. The company now has excellent product varieties, mature technology, and a management team that has been engaged in drug production and sales in high-quality famous pharmaceutical enterprises for nearly 20 years. The company welcomes talents with entrepreneurship, ambition and ambition to join our team to work together to create brilliance. Company address No.9, jing13 Road, Hangzhou Bay Economic and Technological Development Zone, Shangyu District, Shaoxing City, Zhejiang Province Slogan: high quality bamboo pharmaceutical One center: respect market rules and take market as the center Company policy: Double Seven policy